Pfizer stock forecast for 2030. $10B obesity bet and BRAFTOVI approval bets $45 upside

Traders Union
All News
Financial News
PFE BRAFTOVI Approval GLP-1

Pfizer stock consolidates after testing resistance

Pfizer is trading at $26.61, down 0.04%. It has been stuck in a tight range between $26 and $27 since late February, when it hit resistance near $28. The stock is trading above the 100 EMA at $25.56 and the 200 EMA at $24.91, and it is sitting just above the 20 EMA at $26.86 and the 50 EMA at $26.27. The sideways chop shows in the moving averages, which are all pretty flat.

Highlights

Pfizer trades near $26, holding a tight $26–$27 range after rallying from $25 lows.
Stock could reach $38–$48 by 2030 if its GLP-1 drugs capture a share of the $150B obesity market.
PFE wins full BRAFTOVI approval and plans 10 Phase 3 obesity trials in 2026.

PFE price dynamics (Source: TradingView)

The chart indicates that Pfizer moved up from lows near $23 in late 2025 to highs near $28 in early 2026 before pulling back into the current consolidation. RSI sitting at 48.34 settles in neutral territory from overbought levels above 60.

A break above $27.5-28 would unlock the path to $29-30. Support is at the 50 EMA at about $26.27, with stronger support at $25.5 and the 200 EMA around $24.91. Consolidation is likely indecisive in weighing off against the pipeline tale the decline in COVID-related revenues.

Argus upgrades to Buy with a $35 target

On March 2, Argus raised PFE from Hold to Buy, setting a price target of $35. They did this because they saw good progress in the GLP-1 pipeline and strong programs in oncology and hematology.

The average target for the next 12 months is $29.37 per share, with estimates ranging from $24.24 to $39.42. In the last quarter, the number of institutional holders of PFE fell by 11%, but the average portfolio weighting of funds that do hold PFE rose by 13.5%.

$10B GLP-1 bet launches 10 Phase 3 trials in 2026

The $10 billion Metsera acquisition, closed in November 2025, transforms Pfizer into an obesity platform anchored by monthly injectable and oral combination therapies. Phase 2b VESPER-3 data showed the monthly injectable PF'3944 drove up to 12.3% placebo-adjusted weight loss at week 28.

CEO Albert Bourla told CNBC that a higher dose planned for Phase 3 will produce efficacy and tolerability data that is maybe best in class, with company modeling predicting 16% placebo-adjusted weight loss. Pfizer plans 10 Phase 3 trials with PF'3944 in 2026 alone. Bourla projects the obesity drug market will reach $150 billion by 2030.

PFE outlook and valuation path

Pfizer’s valuation reflects the collapse of COVID-19 revenue, not the scale of what is coming next. A $150 billion obesity market changes the math for every large pharmaceutical company.

If Pfizer captures even a small slice while oncology assets like BRAFTOVI expand, the current price starts to look less like a ceiling and more like the market ignoring the next decade of growth.”

Recently, Pfizer consolidated near $26.61 after BRAFTOVI won full FDA approval and Argus upgraded to Buy with a $35 target, as the stock tested the 20 EMA following a rally from $25 lows to $28 resistance.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.